ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HS-20137

A development code.

Its studies are mostly in Psoriasis, led by Hansoh Pharmaceutical Group.

Furthest: phase 3, since Feb 7, 20252 company-led studies, 2 open or runningNext primary completion: Mar 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group22 open or runningphase 3since Feb 7, 2025Feb 7, 2025Mar 1, 2027phase 2 · NCT07879885

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 7, 2025First study: phase 3 study in Moderate-to-severe Plaque PsoriasisFirst studyNCT06844799 · 720 planned
  2. Oct 11, 2026Phase 2 study in Moderate-to-severe Plaque PsoriasisNCT07879885 · 390 planned · China

Ahead

  1. Mar 1, 2027Primary completion: phase 2 study in Moderate-to-severe Plaque PsoriasisNCT07879885
  2. Mar 31, 2027Primary completion: phase 3 study in Moderate-to-severe Plaque PsoriasisNCT06844799

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07879885Moderate-to-severe Plaque Psoriasis · China2RecruitingMar 1, 2027390
NCT06844799Moderate-to-severe Plaque Psoriasis3Not yet recruitingMar 31, 2027720

How it is read

Names in the registry

  • “HS-20137”, 2 entries

Codes read as this program: HS20137.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.